Free Biopharma Daily Stock Updates - 05/27/21

$XBI $128.6 +1.3%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$OCGN +13.7% Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™. source

$XNCR 14-.% Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19. source

Pipeline Updates

$ITRM +3.4% Iterum Therapeutics Provides Update on NDA Review. source

$CHMA +1.4% Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly. source

$BHVN +2.1% FDA Approves Biohaven's NURTEC® ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment. source

$APVO -2.1% Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia. source

$ELOX +5.7% Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents. source

$SLS +4.7% SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies. source

$HZNP -1.7% Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy. source

$DRNA -0.8% Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469. source

$QURE +5.0% uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease. source

$ONCR +1.6% Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788. source

$DVAX +5.7% Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. source

$CNCE 0% Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata. source

$SEEL +6.2% Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS). source

$TLC -4.8% TLC and Strides Enter Agreement for AmphoTLC™ in India. source

$IMNM +17.6% Immunome to Present at the Jefferies Virtual Healthcare Conference. source

$ZSAN +15.7% On 5/26 Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain. source

$APLS +10.1% On 5/25 Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH. source

$PRTA +14.1% On 5/20 Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors. source

$LNTH +16.8% Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer. source

$SYRS +17.2% Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio; initiated on 5/26. source

$RFL +9.5% Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program. source

$PIRS +12.4% Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech. source

Financial Updates

$ANVS -8.5% Annovis Bio, Inc. Announces Closing of $50 Million Public Offering. source

$PRVB 0% Provention Bio Stock Trading Halted Today. source

$NOVN -12.5% Announced 1-for-10 reverse stock split on 5/25/21. source

$PDSB +11.6% PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance. source

---

Posted by FS